All Relations between Alzheimer Disease and cholinergic receptor, nicotinic

Publication Sentence Publish Date Extraction Date Species
Morten Skøtt Thomsen, Ruud Zwart, Daniel Ursu, Majbrit Myrup Jensen, Lars Hageman Pinborg, Gary Gilmour, Jie Wu, Emanuele Sher, Jens Damsgaard Mikkelse. α7 and β2 Nicotinic Acetylcholine Receptor Subunits Form Heteromeric Receptor Complexes that Are Expressed in the Human Cortex and Display Distinct Pharmacological Properties. PloS one. vol 10. issue 6. 2016-05-04. PMID:26086615. since α7-containing nachrs are promising drug targets for schizophrenia and alzheimer's disease, it is critical to determine whether α7β2 nachrs are present in the human brain, in which brain areas, and whether they differ functionally from α7 nachr homomers. 2016-05-04 2023-08-13 mouse
Adriele Silva Alves de Oliveira, Fernando Enrique Santiago, Laiz Furlan Balioni, Merari de Fatima Ramires Ferrari, Maria Camila Almeida, Daniel Carneiro Carrettier. BAG2 expression dictates a functional intracellular switch between the p38-dependent effects of nicotine on tau phosphorylation levels via the α7 nicotinic receptor. Experimental neurology. vol 275 Pt 1. 2016-04-29. PMID:26496817. the histopathological hallmarks present in alzheimer's disease (ad) brain are plaques of aβ peptide, neurofibrillary tangles of hyperphosphorylated tau protein, and a reduction in nicotinic acetylcholine receptor (nachr) levels. 2016-04-29 2023-08-13 rat
Jing-Yi Yu, Bao Zhang, Liang Peng, Chun-Hua Wu, Hong Cao, John F Zhong, Jill Hoffman, Sheng-He Huan. Repositioning of Memantine as a Potential Novel Therapeutic Agent against Meningitic E. coli-Induced Pathogenicities through Disease-Associated Alpha7 Cholinergic Pathway and RNA Sequencing-Based Transcriptome Analysis of Host Inflammatory Responses. PloS one. vol 10. issue 5. 2016-04-11. PMID:25993608. we have demonstrated for the first time that memantine (mem), a fda-approved drug for treatment of alzheimer's disease, could very efficiently block e. coli-caused bacteremia and meningitis in a mouse model of nsm in a manner dependent on α7 nachr. 2016-04-11 2023-08-13 mouse
Olena Lykhmus, Nibha Mishra, Lyudmyla Koval, Olena Kalashnyk, Galyna Gergalova, Kateryna Uspenska, Serghiy Komisarenko, Hermona Soreq, Maryna Sko. Molecular Mechanisms Regulating LPS-Induced Inflammation in the Brain. Frontiers in molecular neuroscience. vol 9. 2016-03-25. PMID:27013966. we previously showed that either bacterial lipopolysaccharide (lps) or immunization with the α7(1-208) nachr fragment decrease α7 nachrs density in the mouse brain, exacerbating chronic inflammation, beta-amyloid accumulation and episodic memory decline, which mimic the early stages of alzheimer's disease (ad). 2016-03-25 2023-08-13 mouse
Morten Grupe, Morten Grunnet, Jesper Frank Bastlund, Anders A Jense. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach. Basic & clinical pharmacology & toxicology. vol 116. issue 3. 2015-11-03. PMID:25441336. the focus of the present minireview is on the heteromeric α4β2 nachr, as activity at this subtype contributes to cognitive functioning through interactions with multiple neurotransmitter systems and is implicated in various cns disorders, for example schizophrenia and alzheimer's disease. 2015-11-03 2023-08-13 Not clear
Mei Huang, Anna R Felix, Dorothy G Flood, Chaya Bhuvaneswaran, Dana Hilt, Gerhard Koenig, Herbert Y Meltze. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology. vol 231. issue 23. 2015-10-07. PMID:24810107. alpha7 and α4β2 nicotinic acetylcholine receptor (nachr) agonists have been shown to improve cognition in various animal models of cognitive impairment and are of interest as treatments for schizophrenia, alzheimer's disease, and other cognitive disorders. 2015-10-07 2023-08-13 rat
Akihiro Matsumura, Syuuichirou Suzuki, Naotoshi Iwahara, Shin Hisahara, Jun Kawamata, Hiromi Suzuki, Ayano Yamauchi, Kazuyuki Takata, Yoshihisa Kitamura, Shun Shimoham. Temporal changes of CD68 and α7 nicotinic acetylcholine receptor expression in microglia in Alzheimer's disease-like mouse models. Journal of Alzheimer's disease : JAD. vol 44. issue 2. 2015-09-21. PMID:25352454. nevertheless, how microglia and α7 nachr in microglia are affected in alzheimer's disease (ad) remains unknown. 2015-09-21 2023-08-13 mouse
Britta Hah. Nicotinic receptors and attention. Current topics in behavioral neurosciences. vol 23. 2015-09-08. PMID:25655889. facilitation of different attentional functions by nicotinic acetylcholine receptor (nachr) agonists may be of therapeutic potential in disease conditions such as alzheimer's disease or schizophrenia. 2015-09-08 2023-08-13 human
Miroslav Pohank. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. International journal of molecular sciences. vol 13. issue 2. 2015-08-26. PMID:22408449. agonists of α7 nachr are suitable for treatment of multiple cognitive dysfunctions such as alzheimer's disease or schizophrenia. 2015-08-26 2023-08-12 Not clear
Marci L Smith, Fred G Oliveira Souza, Kady S Bruce, Christianne E Strang, Barbara J Morley, Kent T Keyse. Acetylcholine receptors in the retinas of the α7 nicotinic acetylcholine receptor knockout mouse. Molecular vision. vol 20. 2015-06-26. PMID:25352741. although reductions in the expression of α7 nachrs are thought to contribute to the memory and visual deficits reported in alzheimer's disease (ad) and schizophrenia , the α7 nachr knockout (ko) mouse is viable and has only slight visual dysfunction. 2015-06-26 2023-08-13 mouse
Corinne Beinat, Tristan Reekie, David Hibbs, Teresa Xie, Thao T Olson, Yingxian Xiao, Andrew Harvey, Susan O'Connor, Carolyn Coles, John Tsanaktsidis, Michael Kassio. Investigations of amide bond variation and biaryl modification in analogues of α7 nAChR agonist SEN12333. European journal of medicinal chemistry. vol 84. 2015-04-17. PMID:25019477. several lines of experimental evidence support the involvement of the α7 nachr in schizophrenia and alzheimer's disease. 2015-04-17 2023-08-13 Not clear
Huaimeng Fan, Ruoxu Gu, Dongqing We. The α7 nAChR selective agonists as drug candidates for Alzheimer's disease. Advances in experimental medicine and biology. vol 827. 2015-03-09. PMID:25387975. the α7 nachr selective agonists as drug candidates for alzheimer's disease. 2015-03-09 2023-08-13 Not clear
Huaimeng Fan, Ruoxu Gu, Dongqing We. The α7 nAChR selective agonists as drug candidates for Alzheimer's disease. Advances in experimental medicine and biology. vol 827. 2015-03-09. PMID:25387975. the α7 nachr is significantly reduced in the patients of alzheimer's disease and is believed to interact with the aβ amyloid. 2015-03-09 2023-08-13 Not clear
Huaimeng Fan, Ruoxu Gu, Dongqing We. The α7 nAChR selective agonists as drug candidates for Alzheimer's disease. Advances in experimental medicine and biology. vol 827. 2015-03-09. PMID:25387975. therefore, the α7 nachr agonists are excellent drug candidates for alzheimer's disease and we summarized here the current agonists that have selectivity of the α7 nachr over the other nachr, introduced recent molecular modeling works trying to explain the molecular mechanism of their selectivity and described the design of novel allosteric modulators in our lab. 2015-03-09 2023-08-13 Not clear
Emile Andriambeloson, Bertrand Huyard, Etienne Poiraud, Stéphanie Wagne. Methyllycaconitine- and scopolamine-induced cognitive dysfunction: differential reversal effect by cognition-enhancing drugs. Pharmacology research & perspectives. vol 2. issue 4. 2014-12-16. PMID:25505596. there is a growing body of evidence pointing to the pivotal role of alpha-7 nicotinic acetylcholine receptor (α7 nachr) dysfunction in cognitive disorders such as alzheimer's disease or schizophrenia. 2014-12-16 2023-08-13 mouse
Eline K M Lebbe, Steve Peigneur, Mohitosh Maiti, Prabha Devi, Samuthirapandian Ravichandran, Eveline Lescrinier, Chris Ulens, Etienne Waelkens, Lisette D'Souza, Piet Herdewijn, Jan Tytga. Structure-function elucidation of a new α-conotoxin, Lo1a, from Conus longurionis. The Journal of biological chemistry. vol 289. issue 14. 2014-05-30. PMID:24567324. because nachrs have an important role in regulating transmitter release, cell excitability, and neuronal integration, nachr dysfunctions have been implicated in a variety of severe pathologies such as epilepsy, myasthenic syndromes, schizophrenia, parkinson disease, and alzheimer disease. 2014-05-30 2023-08-12 xenopus_laevis
Marcelo Pires-Oliveira, Derek Moen, Mohammed Akaaboun. Dynamics of nicotinic acetylcholine receptors and receptor-associated proteins at the vertebrate neuromuscular junction. Current Alzheimer research. vol 10. issue 6. 2014-04-11. PMID:23627754. decreases in postsynaptic nachr density are related to myasthenic syndromes in the peripheral nmj, but are also associated in central synapses with neurodegenerative diseases such as alzheimer's. 2014-04-11 2023-08-12 Not clear
David C Kombo, Anatoly A Mazurov, Jon-Paul Strachan, Merouane Bencheri. Computational studies of novel carbonyl-containing diazabicyclic ligands interacting with α4β2 nicotinic acetylcholine receptor (nAChR) reveal alternative binding modes. Bioorganic & medicinal chemistry letters. vol 23. issue 18. 2014-03-31. PMID:23937977. these findings could be exploited to design diverse and selective novel chemical libraries for the treatment of diseases and conditions where the α4β2 nachr is disrupted, such as alzheimer disease, parkinson's disease and l-dopa-induced dyskinesia (lid). 2014-03-31 2023-08-12 Not clear
Katja S Kroker, Jens Moreth, Lothar Kussmaul, Georg Rast, Holger Rosenbroc. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists. Brain research bulletin. vol 96. 2014-03-19. PMID:23639920. as nicotinic acetylcholine receptor (nachr) agonists directly address cholinergic neurotransmission with potential impact on glutamatergic function, they are considered as potential new symptomatic treatment options for alzheimer's disease compared to the indirectly operating acetylcholinesterase inhibitors such as the current gold standard donepezil. 2014-03-19 2023-08-12 rat
Hayden T Ravert, Peter Dorff, Catherine A Foss, Ronnie C Mease, Hong Fan, Christopher R Holmquist, Eifion Phillips, Dennis J McCarthy, J Richard Heys, Daniel P Holt, Yuchuan Wang, Christopher J Endres, Robert F Dannals, Martin G Pompe. Radiochemical synthesis and in vivo evaluation of [18F]AZ11637326: an agonist probe for the α7 nicotinic acetylcholine receptor. Nuclear medicine and biology. vol 40. issue 6. 2014-02-25. PMID:23680470. a positron-emitting radioligand targeting the α7 nachr would enable better understanding of a variety of neuropsychiatric illnesses, including schizophrenia and alzheimer's disease, and could enhance the development of new drugs for these and other conditions. 2014-02-25 2023-08-12 Not clear